FDA details flexibilities for new cell and gene therapies to leverage past data

June 2, 2026 01:40 PM EDT Cell/Gene TxFDA+ FDA de­tails flex­i­bil­i­ties for new cell and gene ther­a­pies to lever­age past da­ta Zachary Brennan Senior Editor The FDA is fur­ther ex­plain­ing to cell and gene ther­a­py de­vel­op­ers the types of pri­or knowl­edge com­pa­nies can lever­age for clin­i­cal, non­clin­i­cal and man­u­fac­tur­ing-re­lat­ed work … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER